WeLeader Biomedical Co., Ltd. (TPEX:7713)

Taiwan · Delayed Price · Currency is TWD

73.50

+0.60 (0.82%)

Aug 26, 2026, 1:13 PM CST

6.06% (1Y)

Market Cap	3.34B +6.1%
Revenue (ttm)	1.21B +18.4%
Net Income	249.24M +42.2%
EPS	5.05 +24.4%
Shares Out	45.48M
PE Ratio	14.55
Forward PE	n/a
Dividend	4.10 (5.77%)
Ex-Dividend Date	Mar 27, 2026

Volume	16,109
Open	74.00
Previous Close	72.90
Day's Range	73.00 - 74.40
52-Week Range	66.00 - 83.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1992

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 7713

Full Company Profile

Financial Performance

In 2025, WeLeader Biomedical's revenue was 1.11 billion, an increase of 11.92% compared to the previous year's 991.13 million. Earnings were 208.56 million, an increase of 22.53%.

Financial Statements